Yahoo Sport

Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data

Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day. Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound. "Novo's share price today is certainly factoring in some negative reaction to Amgen's positive commentary on MariTide development yesterday," Kepler Cheuvreux analyst David Evans said, but added that "a continued negative reaction to results and pricing concerns yesterday is likely also a smaller part of the move today".